A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
Neoplasms
Interventions
DRUG

ADH -1 (Exherin™)

Trial Locations (11)

27599

Lineberger Comprensive Cancer Center, Chapel Hill

27703

Duke Comprehensive Cancer Centre, Durham

33908

Florida Cancer Specialist, Fort Myers

37203

Sarah Cannon Research Institute, Nashville

37404

Chattanooga Oncology and Hematology Associates, Chattanooga

Unknown

Cross Cancer Institute, Edmonton

BC Cancer Agency - Vancouver Centre, Vancouver

Centre for Clinical Research, Halifax

K1H 1C4

The Ottawa Hospital Regional Cancer Center (TOHRCC), Ottawa

M5G 2M9

Princess Margaret Hospital, Toronto

H3T 1E2

McGill University Jewish General Hospital, Montreal

Sponsors
All Listed Sponsors
lead

Adherex Technologies, Inc.

INDUSTRY

NCT00264433 - A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent | Biotech Hunter | Biotech Hunter